Nextvivo

Developer of immune-competent human-derived models for drug development

placePalo Alto, California, United States calendar_todayFounded 2021 groups8 employees language nextvivo.bio

Innovation

2 patent families — focus: Human necessities; filing pace active. Cited 4 times.

YearFilings
20241
20252

Investor mix

4 investors on record; lead investors include Khosla Ventures.

Investor typeCountShare
Venture capital125%
Bank & private debt125%
Other / undisclosed250%
Coming soon